The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C

Journal of Viral Hepatitis

Volumn 10, Issue 2, 2003, Pages 103-110

  Myers, R P ^a   Thibault, V ^b   Poynard, Thierry ^a,b  

^a Dept of Hepatol/Gastroenterology ^*  (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Fibrosis; Interferon; Prognosis; Response; Ribavirin; Treatment

Indexed keywords

HEPATITIS B CORE ANTIGEN; INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; CONFIDENCE INTERVAL; DRUG RESPONSE; FEMALE; GENDER; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KAPLAN MEIER METHOD; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERSISTENT VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 12244264843     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00407.x     Document Type: Article

References (28)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345(1): 41-52.
2. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P. Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001; 8(1): 48-62.
3. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352(9138): 1426-1432.
4. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1485-1492.
5. Weltman MD, Brotodihardjo A, Crewe EB et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2(1): 39-45.
6. Liaw YF, Chien RN, Lin SM et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997; 17(8): 449-452.
7. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME. Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341(1): 22-26.
8. De Maria N, Colantoni A, Friedlander L et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000; 95(12): 3529-3536.
9. Sagnelli E, Coppola N, Scolastico C. et al. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. J Med Virol 2001; 65(4): 681-687.
10. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and 'silent' HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001; 64(3): 350-355.
11. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S. Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely 'occult'? Hepatology 2001; 34(1): 194-203.
12. Villa E, Grottola A, Buttafoco P et al. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B. Dig Dis Sci 1995; 40(1): 8-13.
13. Dutta U, Byth K, Kench J et al. Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study. Aust N Z J Med 1999; 29(3): 300-307.
14. Shibata Y, Nakata K, Tsuruta S et al. Detection of hepatitis B virus X-region DNA in liver tissue from patients with hepatitis C virus-associated cirrhosis who subsequently developed hepatocellular carcinoma. Int J Oncol 1999; 14(6): 1153-1156.
15. Fukuda R, Ishimura N, Niigaki M et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999; 58(3): 201-207.
16. Zignego AL, Fontana R, Puliti S et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997: 51(4): 313-318.
17. Zignego AL, Fontana R, Puliti S et al. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol 1997; 142(3): 535-544.
18. Bonino F. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998; 351(9115): 1535-1539.
19. Stuyver L, Rossau R, Wyseur A et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74(Pt 6): 1093-1102.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24(2): 289-293.
21. Poynard T. Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349(9055): 825-832.
22. Thomas DL. Vlahov D, Solomon L. et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995: 74(4): 212-220.
23. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100(1): 182-188.
24. Dickson RC, Everhart JE, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997: 113(5): 1668-1674.
25. Fukuda R, Ishimura N, Hamamoto S et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 2001: 63(3): 220-227.
26. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337(8746): 867-872.
27. Uchida T, Kaneita Y, Gotoh K et al. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus: probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection. J Med Virol 1997: 52(4): 399-405.
28. Manns MP. McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001: 358(9286): 958-965.